Psychedelic Weekly Headlines | June 17th

June 17, 2022
Headlines

Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.


Markets

Performance of psychedelic public companies this past week.


Company News

Mydecine Innovations Group ($MYCO | $MYCOF) announced that the FDA has cleared MYCO-001 in a recent IND application, marking the first clearance of Mydecine's drug product. The Investigator Initiated trial is funded by a $4 million grant from the National Institutes of Health, making this the first time in 50 years the U.S. government has funded a study evaluating a psychedelic compound for therapeutic use. Press Release

Nova Mentis Life Science ($NOVA | $NMLSF) filed a patent on diagnosing, monitoring and treating neurological diseases with psilocybin and psilocybin-based tryptamine derivatives. Nova Mentis recently successfully completed a preclinical study that confirmed oral microdose psilocybin as a potential treatment option for ASD and FXS. Press Release

Revitalist Lifestyle And Wellness ($CALM | $RVLWF) closed their second tranche of its private placement, bringing the total gross proceeds raised to $3.9 million. Since opening their first clinic in 2018, Revitalist has provided thousands of ketamine infusions. Press Release

Braxia Scientific ($BRAX | $BRAXF) opened their newest Braxia Health clinic in Ontario, focused on intravenous and oral ketamine, and psilocybin for treatment resistant depression and other mental health disorders. This is Braxia's fifth Health Clinic in Canada. Press Release

Awakn Life Sciences ($AWKN | $AWKNF) provided operational updates. Highlights included the completetion of the world's first Ketamine study for a range of behavioral addictions, regulatory approval for flagship clinic in London to begin delivering treatments and initiated a follow-on behavioral study investigating ketamine as a treatment for gambling disorder. Press Release

Irwin Naturals ($IWIN | $IWINF) acquired Preventive Medicine, a clinic operation based in Colchester, Vermont. This is Irwin Naturals' eighth ketamine clinic, which now covers four states. Press Release

Beckley Psytech (Private) partnered with Ksana Health to support the collection and analysis of digital behavioural data in Beckley Psytech’s upcoming Phase II studies evaluating the use of DMT in combination with psychotherapy as a potential treatment of treatment resistant depression. Press Release

Filament Health ($FH | $FLHLF) announced that a patient has been dosed with one of Filament's drug candidates through the Health Canada Special Access Program. Press Release


Media

Psychedelic Finance: Interview With Amanda Feilding Of Beckley Foundation

Netflix: How To Change Your Mind | Official Trailer (Video)

CNN: How Psilocybin May Rewire The Brain To Ease Depression, Anxiety And More

New York Post: Psychedelics May Help Ease The Elderly And Terminally Ill Into Afterlife

Fox: New OSU Academic Center To Focus On Psychedelic Drug Research


Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.